On May 28, 2026 Low Institute for Therapeutics (LIFT), a pioneering non-profit clinical research organization, and NorthStar Medical Radioisotopes, LLC (NorthStar), a leading radiopharmaceutical company reported a strategic collaboration to accelerate the development, manufacturing, and clinical translation of Lu177-LT17, a novel Lutetium-177 based radioligand therapy candidate for the treatment of cancer-associated bone disease, including hematologic malignancies and metastatic solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Through the partnership, NorthStar will provide integrated radiopharmaceutical contract development and manufacturing (CDMO) capabilities, including LT17 isotope radiolabeling, analytical development, and current Good Manufacturing Practice (cGMP) manufacturing support. The collaboration will support key translational and regulatory milestones aimed at supporting an Investigational New Drug (IND) application. Once approved, NorthStar will manufacture the clinical supply for planned Phase I first in-human trials.
"Our collaboration with LIFT reinforces NorthStar’s position as a preferred contract development and manufacturing partner across the radiopharmaceutical ecosystem, including with nonprofit and academic-led programs," said Dr. Frank Scholz, President & CEO of NorthStar. "By combining our end-to-end CDMO capabilities with LIFT’s research model, we are helping bring promising new therapies closer to patients who need them most."
Lu177-LT17 is a highly targeted radioligand therapy designed to selectively deliver therapeutic radioisotopes to cancer-induced bone lesions while minimizing exposure to surrounding healthy tissue. The program reflects the growing momentum across the radiopharmaceutical sector as precision oncology and targeted radioligand therapies continue advancing toward broader clinical adoption.
"LIFT was founded with a mandate to advance the groundbreaking discoveries coming out of Purdue University into transformative therapies for patients," said Dr. Stewart Low, Executive Director of LIFT. "Lu177-LT17 is a compelling example of that mandate being put into action. Partnering with NorthStar provides the expertise and infrastructure necessary to advance Lu177-LT17 into the clinic and ultimately, help patients in need."
For NorthStar, the collaboration further expands the company’s role as an integrated radiopharmaceutical partner supporting early development, isotope production and supply, and cGMP manufacturing for emerging radiopharmaceutical programs. NorthStar’s vertically integrated infrastructure was purpose-built to support seamless radiopharmaceutical development, scale-up, and long-term commercialization, enabling programs to advance from early clinical development through commercial readiness within a coordinated operational environment.
(Press release, NorthStar Medical Radiostopes, MAY 28, 2026, View Source [SID1234666184])